LivaNova PLC is a renowned company that upholds strong values and a distinctive corporate philosophy. With a commitment to improving patients' lives, LivaNova PLC focuses on delivering innovative medical solutions to enhance healthcare outcomes. The company believes in prioritizing patients' well-being, collaborating with healthcare professionals, and fostering a culture of excellence to drive positive change in the industry. LivaNova PLC's dedication to integrity, teamwork, and patient-centricity has earned them recognition as a trusted global leader in medical technology.

LivaNova PLC is primarily present in numerous countries and regions worldwide. The company has a strong global presence and operates in key markets such as the United States, Europe, Asia Pacific, and the Middle East. With its headquarters in London, United Kingdom, LivaNova PLC has established a significant presence in these regions, leveraging its expertise in medical technology and innovative solutions. By focusing on these strategic markets, LivaNova PLC aims to provide its cutting-edge products and therapies to patients and healthcare professionals across the globe.

LivaNova PLC, a renowned company in the stock market, has accomplished several significant milestones. Firstly, the company successfully developed and launched its groundbreaking VNS Therapy System, a revolutionary treatment for drug-resistant epilepsy and depression. LivaNova PLC also expanded its reach by acquiring TandemLife, a leading provider of advanced cardiopulmonary support solutions. Additionally, the company achieved FDA approval for several innovative medical devices, including the Perceval Sutureless Heart Valve and the SenTiva VNS Therapy System. LivaNova PLC's commitment to continuous innovation and exceptional healthcare solutions has led to remarkable advancements and cemented its position as an industry leader.

LivaNova PLC is a renowned global medical technology company, specializing in the development and delivery of innovative healthcare solutions. Established in 2015, LivaNova was formed as a result of a merger between Sorin Group, an established leader in the cardiac surgery market, and Cyberonics, a pioneer in the field of neuromodulation. With a rich history spanning decades, LivaNova PLC continues to make significant contributions in the areas of cardiovascular and neuromodulation therapies, aiming to improve patient outcomes and quality of life. The company is committed to advancing medical technology through continual research and development efforts, offering a diverse portfolio of products and services to address a wide range of medical needs.

Some of the main competitors of LivaNova PLC in the market include Medtronic, Abbott Laboratories, and Boston Scientific Corporation.

LivaNova PLC is primarily active in the industries of medical devices and therapies.

The business model of LivaNova PLC focuses on developing and commercializing innovative medical technology solutions in the fields of cardiovascular and neuromodulation. As a global medical device company, LivaNova PLC is committed to enhancing patient outcomes and transforming patients' lives. Their diverse product portfolio includes advanced devices and therapies for cardiac surgery, heart failure, and other cardiovascular conditions, as well as treatments for epilepsy and depression. Through research, development, and strategic collaborations, LivaNova PLC aims to provide healthcare professionals with effective solutions to improve patient care and quality of life.

สัดส่วนราคาต่อกำไรของ LivaNova คือ 12.89

KUV ของ LivaNova คือ 1.93

AlleAktien คุณภาพสกอร์สำหรับ LivaNova คือ 3/10.

คาดหวัง LivaNova มียอดขายอยู่ที่ 1.34 ล้านล้าน USD

กำไร คาดหวัง LivaNova คือ 201.12 ล้าน USD

LivaNova PLC is a global medical technology company that develops, manufactures, and distributes innovative solutions for patients with cardio-pulmonary disease as well as for neuromodulation and neurosurgery applications. It was formed in 2015 as a merger between the Italian Sorin Group and the US-based Cyberonics and is headquartered in London. LivaNova's business model is focused on advancing medical progress through technology, innovation, and collaboration with leading clinical partners. The company operates in three main areas: cardiology, neuromodulation, and neurosurgery. LivaNova's cardiology division focuses on developing products and procedures for the treatment of cardiovascular diseases. These include artificial heart valves and surgical instruments for procedures such as bypass surgeries and trans-septal interventional procedures. These products are used in patients with congenital heart defects, coronary artery disease, and valve diseases. The neuromodulation division of LivaNova includes the development of implantable devices for the treatment of epilepsy and depression. The company is well positioned to benefit from the growing markets for neuromodulatory therapies. One product from LivaNova is the vagus nerve stimulator, which is used for the treatment of epilepsy, depression, and other neurological disorders. LivaNova's neurosurgery division specializes in the development of devices and technologies for the treatment of brain diseases and injuries. This includes invasive neurostimulators, devices for cerebral temperature measurement, and devices for monitoring brain functions during surgeries. These products are used by neurosurgeons and neurologists for the diagnosis and treatment of patients with brain diseases and injuries. LivaNova is committed to continuously developing and improving new products and services to meet the needs of healthcare facilities and patients. The company works closely with leading clinical partners to test and enhance the effectiveness of its products. Collaboration with universities, medical centers, and other research institutions allows LivaNova to share its technology and expertise with leading clinics worldwide, maximizing the potential of its products and services. The company also provides innovative digital solutions to support patients with cardiovascular and neurological diseases. The MyLivaNova platform serves as a tool for patients to take control of their health and collaborate closely with their doctors and healthcare professionals. LivaNova's business model is focused on positioning the company as a leading provider of medical technology products and services. The company is committed to improving people's lives through innovative technologies and treatment options. With a wide range of products and a strong presence in the global market, LivaNova is well positioned to continue growing and remaining innovative in the coming years.

LivaNova จ่ายเงินปันผล 0 USD ผ่าน ครั้งในหนภายในหนึ่งปี.

ปัจจุบันไม่สามารถคำนวณเงินปันผลสำหรับ LivaNova หรือบริษัทไม่จ่ายเงินปันผล.

ISIN ของ LivaNova คือ GB00BYMT0J19

WKN ของ LivaNova คือ A14156.

ตัวย่อของ LivaNova คือ LIVN

ภายในช่วง 12 เดือนที่ผ่านมา LivaNova จ่ายเงินปันผลทั้งหมด นี้เทียบเท่ากับอัตราผลตอบแทนจากเงินปันผลประมาณ สำหรับ 12 เดือนข้างหน้า LivaNova คาดว่าจะจ่ายเงินปันผลทั้งหมด 0 USD

อัตราผลตอบแทนเงินปันผลของ LivaNova ในปัจจุบันคือ

LivaNova จ่ายเงินปันผลทุกไตรมาส การจ่ายเงินปันผลจะเกิดขึ้นในเดือน

LivaNova จ่ายเงินปันผลทุกปีในช่วง 0 ปีที่ผ่านมา.

คาดว่าในช่วง 12 เดือนข้างหน้าจะมีการจ่ายเงินปันผลทั้งหมด 0 USD ซึ่งเทียบเท่ากับผลตอบแทนจากเงินปันผลร้อยละ 0 %

LivaNova ถูกจัดให้อยู่ในภาคส่วน 'สุขภาพ'

เพื่อรับเงินปันผลล่าสุดของ LivaNova ในวันที่ 9/2/2568 ที่มูลค่า 0 USD คุณจะต้องถือหุ้นไว้ในพอร์ตก่อนวันที่เป็น Ex-Tag ในวันที่ 9/2/2568

การจ่ายเงินปันผลครั้งล่าสุดเกิดขึ้นเมื่อวันที่ 9/2/2568

ในปี 2024 บริษัท LivaNova ได้จ่ายเงินปันผลเป็นจำนวน 0 USD

เงินปันผลของ LivaNova จะถูกจ่ายใน USD